Where Device VCs Have Gone Before
This article was originally published in Start Up
Executive Summary
A deep dive of the portfolios of nearly three dozen device VCs shows that they’ve invested in certain therapeutic categories in the past including ophthalmic, cardiovascular, metabolic disease and spine. Like digging through soil to determine the climate conditions of eons past, the totals tell more about where the VC industry has been rather than where it’s going. But the past is sometimes of good indicator of what’s to come in both life and venture capital.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.